Maravai LifeSciences Q1 2024 Adj EPS $(0.02) Beats $(0.03) Estimate, Sales $64.179M Beat $60.548M Estimate
Maravai LifeSciences Q1 2024 Adj EPS $(0.02) Beats $(0.03) Estimate, Sales $64.179M Beat $60.548M Estimate
Maravai LifeSciences 2024年第一季度调整后每股收益美元（0.02）超过预期（0.03），销售额为6,417.9万美元超过预期的6,0548万美元
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 166.67 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $64.179 million which beat the analyst consensus estimate of $60.548 million by 6.00 percent. This is a 18.79 percent decrease over sales of $79.025 million the same period last year.
Maravai LifeSciences（纳斯达克股票代码：MRVI）公布的季度亏损为每股0.02美元（0.02美元），比分析师普遍预期的0.03美元（0.03美元）高出33.33％。与去年同期的每股收益0.03美元相比，下降了166.67％。该公司公布的季度销售额为6417.9万美元，比分析师普遍预期的6,0548万美元高出6.00％。这比去年同期的7902.5万美元的销售额下降了18.79％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。